However, the increasing entry of generic drug manufacturing firms is threatening the market share of big pharmaceutical companies.
New analysis from Frost & Sullivan (pharma.frost.com), Strategic Analysis of the Kenyan Hypertension Markets, finds that the market earned revenues of $26.0 million in 2007 and estimates this to reach $34.0 million in 2012.
"The rise of the middle class and drastic changes in their lifestyle has led to a sharp increase in the number of cases recorded in the past few years," notes Frost & Sullivan Research Analyst Lizelle Wentzel. "At the same time, many more patients can seek treatment due to having better access to healthcare services and health insurance from their workplaces."
ACE inhibitors are the most commonly used active ingredient because of their low prices. While public hospitals normally offer ACE inhibitors and diuretics because they are cheaper, diuretics and centrally acting anti-hypertensive drugs are not produced by the market leaders due to profitability issues. There is also a growing trend towards calcium channel blockers, which are found to be highly effective.
However, price cutting by generic firms is proving to be a major challenge for ethical drug manufacturers. Moreover, there is insufficient patent protection for ethical drug manufacturers and therefore generics enter the market soon after the ethical drug has gained acceptance.
"Generic drugs are gaining market share through volumes and are favoured for government tenders because of their low price," says Wentzel. "It is also common to find a generic entering the Kenyan hypertension market before the ethical drug."
Given this challenge, a price floor may well be required to prevent further price drops and maintain market attractiveness.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an outline of the strategic analysis of the Kenyan hypertension markets, then send an email to Patrick Cairns, Corporate Communications, at patrick.cairns[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.
Strategic Analysis of the Kenyan Hypertension Markets is part of the Pharmaceutical and Clinical Diagnostics Growth Partnership Service programme, which also includes research in the following markets: Emerging Therapies for Diabetes (Technical Insights), U.S. Heart Failure Therapeutics Markets and Digital Blood Pressure Meters Digital Thermometers and Nebulizer Markets in Indonesia. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.
Strategic Analysis of the Kenyan Hypertension Markets M1F6